Ocugen Stock News

Ocugen (NASDAQ:OCGN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Analyst Ratings This is a summary of current recommendations and price targets for Ocugen and Acumen […]

Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics.

Ocugen, Inc. (OCGN) with the stream of -2.45% also noticed, India CEMEX, S.A.B. de C.V. (CX) encountered a rapid change of -2.23% in the last hour of Wednesdays trading session. The post Stock with unusually volume activity: Ocugen, Inc. (NASDAQ:OCGN), CEMEX, S.A.B. de C.V. (NYSE:CX) appeared first on Stocks Equity .

InvestorPlace - Stock Market News, Stock Advice & Trading Tips OCGN stock may spike once again on positive news, but investors'' best best is to steer clear of it at this point in time. The post Think Twice Before You Roll the Dice on Ocugen Stock appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

Bharat Biotech''s vaccine was found to be 50% effective at preventing symptomatic COVID-19 in a high-risk population during the second wave of infections in India this year, data gleaned from hospital workers showed. Bharat Biotech''s U.S. partner, Ocugen Inc (NASDAQ: OCGN ), has submitted a request to the U.S. FDA for emergency use approval. The real-world study for Covaxin, conducted between Full story available on Benzinga.com

OCGN stock may spike once again on positive news, but investors' best best is to steer clear of it at this point in time. The post Think Twice Before You Roll the Dice on Ocugen Stock appeared first o

Bharat Biotech's vaccine was found to be 50% effective at preventing symptomatic COVID-19 in a high-risk population during the second wave of infections in India this year, data gleaned from hospital

Will either of these hopeful vaccine makers continue to thrash the market?

Credit Suisse AG grew its holdings in shares of Ocugen, Inc. (NASDAQ:OCGN) by 444.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 115,591 shares of the companys stock after purchasing an additional 94,366 shares during the period. Credit Suisse AGs holdings in Ocugen were worth $928,000 at the end of the most recent reporting []

Will either of these hopeful vaccine makers continue to thrash the market?

In the last trading session, 11.69 million shares of the Ocugen Inc. (NASDAQ:OCGN) were traded, and its beta was 4.60. Most recently the companys share price was $7.58, and it changed around -$0.14 or -1.81% from the last close, which brings the market valuation of the company to $1.42B. OCGN currently trades at a discount Ocugen Inc. (NASDAQ: OCGN): Get Ready For The Next Few Months Read More »

Ocugen (NASDAQ:OCGN) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations. Profitability This table compares Ocugen and SpringWorks Therapeutics net margins, return on equity and return on assets. []

Both vaccine makers still have big hurdles to jump.

There's more to this potential coronavirus vaccine stock than what happens in the next 12 months.

There was some highly encouraging news about coronavirus vaccines, but not the one the company is associated with.